Full Logo - OKYO .jpg
OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction
31 oct. 2023 07h00 HE | OKYO Pharma LTD
Pricing of a registered direct offering for $1.64M of 1,092,600 ordinary shares at an offering price of $1.50 per ordinary shareSimultaneous extinguishment of $4.20M of payables by issuing 2,766,667...
Full Logo - OKYO .jpg
OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)
09 oct. 2023 07h00 HE | OKYO Pharma LTD
OKYO plans to initiate a 40-patient OK-101 open-label clinical trial in Q1 2024 with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with...
Full Logo - OKYO .jpg
OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")
05 oct. 2023 07h00 HE | OKYO Pharma LTD
Over 95% of randomized DED patients have completed 4 weeks of dosing in the planned 12-week Phase 2 trial, with 72% of randomized DED patients completing 8 weeks, and 7.1% of patients completing the...
Full Logo - OKYO .jpg
OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares
15 sept. 2023 07h00 HE | OKYO Pharma LTD
LONDON and NEW YORK, Sept. 15, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101...
Full Logo - OKYO .jpg
OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares
14 sept. 2023 09h15 HE | OKYO Pharma LTD
LONDON and NEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101...
Full Logo - OKYO .jpg
OKYO Pharma Limited Announces Withdrawal of Public Offering
14 sept. 2023 08h45 HE | OKYO Pharma LTD
LONDON and NEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101...
Full Logo - OKYO .jpg
OKYO Pharma Announces Public Offering of Ordinary Shares
13 sept. 2023 16h05 HE | OKYO Pharma LTD
LONDON and NEW YORK, Sept. 13, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101...
Full Logo - OKYO .jpg
OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease
08 sept. 2023 07h00 HE | OKYO Pharma LTD
Full enrollment achieved on September 6th with a total of 240 patients enrolled in studyTop-line data planned for release in December 2023Phase 2 trial is designed as a potential registration trial,...
Full Logo - OKYO .jpg
OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)
30 août 2023 07h00 HE | OKYO Pharma LTD
Full enrollment anticipated by first week of SeptemberOKYO on schedule to release top-line data before end of 2023Phase 2 trial is designed as potential registration trial with pre-specified primary...
Full Logo - OKYO .jpg
OKYO Pharma Limited Regains Compliance with Nasdaq Listing Minimum Market Value Rule
29 août 2023 07h00 HE | OKYO Pharma LTD
NEW YORK and LONDON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to...